BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23589229)

  • 1. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang H; Xi S; Liu Z; Yang Y; Zheng Q; Wang F; Xu Y; Wang Y; Zheng Y; Sun G
    Environ Toxicol; 2013 May; 28(5):267-75. PubMed ID: 23589229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang Z; Zhou J; Lu X; Gong Z; Le XC
    Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide.
    Zhao Q; Guo M; Hostetter TH; Chen H; Lin L; Hai X
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1173-1182. PubMed ID: 34181499
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide.
    Lu J; Yu K; Fan S; Liu W; Dong Z; Li J; Wang X; Hai X; Zhou J
    Toxicol Appl Pharmacol; 2019 Sep; 379():114687. PubMed ID: 31330140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
    Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X
    Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide.
    Lu J; Hu S; Wang W; Li J; Dong Z; Zhou J; Hai X
    Toxicol Sci; 2018 Nov; 166(1):219-227. PubMed ID: 30376134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
    Fukai Y; Hirata M; Ueno M; Ichikawa N; Kobayashi H; Saitoh H; Sakurai T; Kinoshita K; Kaise T; Ohta S
    Biol Pharm Bull; 2006 May; 29(5):1022-7. PubMed ID: 16651738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
    Gupta S; Bagel B; Gujral S; Subramanian PG; Khattry N; Menon H; Nair R
    Leuk Lymphoma; 2012 Nov; 53(11):2192-4. PubMed ID: 22452590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Camacho LH; Soignet SL; Chanel S; Ho R; Heller G; Scheinberg DA; Ellison R; Warrell RP
    J Clin Oncol; 2000 Jul; 18(13):2620-5. PubMed ID: 10893295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
    Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
    Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
    Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperleukocytosis from arsenic trioxide.
    Levy M; Wofford MM; Powell BL; McLean TW
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
    Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
    Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
    Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients.
    Wu M; Pang C; Lu S; Hostetter TH; Hai X
    Environ Toxicol Pharmacol; 2023 Jun; 100():104142. PubMed ID: 37146668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3.
    Šlejkovec Z; Podgornik H; Černelč P; Falnoga I
    Biometals; 2016 Feb; 29(1):107-18. PubMed ID: 26671504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
    J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
    Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
    Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.